RxDoctor Payments Data

Martha Ozo

Psychiatric/Mental Health · Mesquite, TXNPI 1407319197

Payments from drug & device makers

$804in general payments, 2019–2025

Across 25 payments — averaging $32.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$336
  • Teva Pharmaceuticals USA, Inc.$195
  • Otsuka America Pharmaceutical, Inc.$161
  • Johnson & Johnson$42
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$26
  • Alkermes, Inc.$22
  • plus $21 from 1 others

What the payments were for

  • Food & beverage$804100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$804 in reported general payments places this provider in the 55th percentile of 2,724 psychiatric/mental health providers in Texas.

See all psychiatric/mental health providers in Texas

Medicare billing

Part B allowed, 2024
$8,897
Medicare patients
33
Services billed
139

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega TrinzaPaliperidone Palmitate15$149,849
IngrezzaValbenazine Tosylate14$120,423
Invega SustennaPaliperidone Palmitate21$54,011
VraylarCariprazine Hcl25$37,125
RexultiBrexpiprazole21$32,644
CaplytaLumateperone Tosylate13$24,445
Lurasidone Hcl43$6,498
Aripiprazole67$5,286
Clozapine51$3,257
Buspirone Hcl163$2,934
Trazodone Hcl225$2,824
Divalproex Sodium ErDivalproex Sodium41$1,978
Hydroxyzine Hcl81$1,652
Duloxetine Hcl81$1,574
Oxcarbazepine30$1,519

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Trinza, Invega Sustenna$42$203,86036 claims
Neurocrine Biosciences, Inc.Ingrezza$21$120,42314 claims
AbbVieVraylar$336$37,12525 claims
Otsuka America Pharmaceutical, Inc.Rexulti$161$32,64421 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$26$24,44513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,724 psychiatric/mental health providers in Texas.

Other psychiatric/mental health in Mesquite

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →